Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiotech Gwth Regulatory News (BIOG)

Share Price Information for Biotech Gwth (BIOG)

Share Price is delayed by 15 minutes
Get Live Data
1,448.00    44.00 (3.13%)
Bid:
1,436.00
Ask:
1,454.00
Spread: 18.00 (1.253%)
Market Cap: £278.85m
BIOG Live PriceLast checked at - London Stock Exchange

Intraday Biotech Gwth Share Chart

Appointment of New Director

4 Sep 2024 12:35

The Biotech Growth Trust PLC - Appointment of New Director

The Biotech Growth Trust PLC - Appointment of New Director

PR Newswire

LONDON, United Kingdom, September 04

4 September 2024

 

THE BIOTECH GROWTH TRUST PLC

(the "Company")

 

 

Appointment of New Director

 

 

The Board of The Biotech Growth Trust PLC is pleased to announce the appointment of Julie Tankard as an independent non-executive director of the Company, with effect from 3 September 2024. Mrs Tankard has been appointed as the Audit Committee Chair-elect and is expected to succeed the current Audit Committee Chair, Julia Le Blan, after Mrs Le Blan retires at the Company's next annual general meeting in July 2025.

 

Mrs Tankard is a non-executive director and chair of the audit committee of F&C Investment Trust PLC. She has 30 years of varied finance experience and is a Fellow of the Chartered Institute of Management Accountants. She is a director of Fincom Advisory Limited providing commercial advice to businesses, having previously been the Chief Financial Officer and a Board member of the Port of London where, as well as finance, she was responsible for risk, procurement, legal and information technology. She was also a trustee of a defined benefit pension scheme for six years, working with investment advisors, the scheme actuary and pensions advisory committee. She sits on the Industrial Development Advisory Board and previously chaired the audit committee of Leeds & York NHS Foundation Trust, prior to which she held various senior positions at BT plc.

 

The Chair of The Biotech Growth Trust PLC, Roger Yates, commented:

 

"We are delighted to welcome Julie Tankard to our Board. With her extensive and varied experience in finance, she will bring valuable insights to the Board and the Audit Committee, where her leadership will be instrumental in guiding our financial oversight and governance."

 

Mrs Tankard has also been appointed to the Company's Audit Committee, Management Engagement Committee, Nominations Committee and Valuation Committee with effect from 3 September 2024. Her appointment will be proposed to shareholders for election at the Annual General Meeting of the Company to be held in July 2025.

 

There is no further information to be disclosed under Listing Rule 9.6.13R(2) to (6).

 

 

 

 

Frostrow Capital LLP

Company Secretary

020 3709 8734

 



Date   Source Headline
23rd Jun 202612:46 pmPRNNet Asset Value(s)
22nd Jun 20262:34 pmPRNNet Asset Value(s)
19th Jun 20265:10 pmPRNTransaction in Own Shares
19th Jun 20261:44 pmPRNNet Asset Value(s)
18th Jun 20261:05 pmPRNNet Asset Value(s)
17th Jun 20261:01 pmPRNNet Asset Value(s)
16th Jun 202612:48 pmPRNNet Asset Value(s)
15th Jun 202612:43 pmPRNNet Asset Value(s)
12th Jun 20265:39 pmPRNTransaction in Own Shares
12th Jun 20263:48 pmPRNNet Asset Value(s)
11th Jun 20261:32 pmPRNNet Asset Value(s)
10th Jun 20263:07 pmPRNMonthly Fact Sheet as at 31 May 2026
10th Jun 20261:33 pmPRNNet Asset Value(s)
9th Jun 20261:57 pmPRNGSK plc to acquire BIOG portfolio company, Nuvalent, Inc.
9th Jun 202612:47 pmPRNNet Asset Value(s)
8th Jun 20261:58 pmPRNNet Asset Value(s)
5th Jun 20265:29 pmPRNTransaction in Own Shares
5th Jun 20262:57 pmPRNNet Asset Value(s)
4th Jun 20262:23 pmPRNNet Asset Value(s)
3rd Jun 20263:56 pmPRNNet Asset Value(s)
3rd Jun 20267:00 amPRNAnnual Financial Report
2nd Jun 202612:32 pmPRNNet Asset Value(s)
1st Jun 20263:04 pmPRNNet Asset Value(s)
1st Jun 202611:12 amPRNTotal Voting Rights
29th May 20265:22 pmPRNTransaction in Own Shares
29th May 20261:56 pmPRNNet Asset Value(s)
28th May 202612:52 pmPRNNet Asset Value(s)
27th May 20261:40 pmPRNNet Asset Value(s)
26th May 20261:15 pmPRNNet Asset Value(s)
22nd May 20265:19 pmPRNTransaction in Own Shares
22nd May 20261:30 pmPRNNet Asset Value(s)
21st May 20261:47 pmPRNNet Asset Value(s)
20th May 20261:07 pmPRNNet Asset Value(s)
19th May 20263:56 pmPRNNet Asset Value(s)
18th May 20262:33 pmPRNNet Asset Value(s)
15th May 20265:30 pmPRNTransaction in Own Shares
15th May 20263:00 pmPRNNet Asset Value(s)
14th May 20265:16 pmPRNMonthly Fact Sheet as at 30 April 2026
14th May 20261:02 pmPRNNet Asset Value(s)
13th May 20262:46 pmPRNNet Asset Value(s)
12th May 20261:02 pmPRNNet Asset Value(s)
11th May 20261:33 pmPRNNet Asset Value(s)
8th May 20265:21 pmPRNTransaction in Own Shares
8th May 20261:56 pmPRNNet Asset Value(s)
7th May 202612:58 pmPRNNet Asset Value(s)
6th May 20262:09 pmPRNNet Asset Value(s)
5th May 20261:49 pmPRNNet Asset Value(s)
1st May 20265:32 pmPRNCompliance with Market Abuse Regulation
1st May 20265:20 pmPRNTransaction in Own Shares
1st May 20262:47 pmPRNARCHIMED to acquire BIOG portfolio company, Esperion Therapeutics.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.